Core Insights - Femasys Inc. will showcase its innovative fertility solutions at the ASRM 2025 Scientific Congress & Expo in San Antonio, Texas from October 25-29 [1][4] - The company is highlighting its next-generation artificial insemination solution, FemaSeed, which has demonstrated more than double the pregnancy rates of traditional intrauterine insemination (IUI) in cases of low male sperm count [2][5] - Femasys has expanded its FemaSeed portfolio to include various kits that enable gynecologists to perform sperm preparation and offer FemaSeed directly in their practices [3] Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally [5] - The company has a patent-protected portfolio of therapeutic and diagnostic products, including FemaSeed and FemVue, aimed at improving reproductive health [5] - Femasys has received regulatory approvals for its products in multiple regions, including the U.S., Europe, UK, Canada, Israel, Australia, and New Zealand [2][6] Product Highlights - FemaSeed is positioned as a safe, accessible, and cost-effective alternative to IUI, particularly for patients with low male sperm count [2] - The FemBloc product, a non-surgical permanent birth control solution, received full regulatory approval in Europe, the UK, and New Zealand in 2025 [6] - The FemChec diagnostic product provides an ultrasound-based test to confirm procedural success for FemBloc [6]

Core Insights - Femasys Inc. has partnered with Kebomed to commercialize FemBloc Permanent Birth Control in France and the Benelux region, significantly enhancing market access for this innovative product [1][2] - The collaboration is a key part of Femasys' European growth strategy following the recent CE mark approval for FemBloc, which is the only non-surgical permanent birth control option available [1][4] Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally, with a patent-protected portfolio of products [3] - The company's lead product innovations include FemBloc and FemaSeed, with clinical data showing FemaSeed is over twice as effective as traditional IUI [3] Product Details - FemBloc is a non-surgical solution for permanent birth control that uses a patented delivery system to occlude fallopian tubes, offering a safer and more cost-effective alternative to surgical sterilization [2][4] - The product has received full regulatory approval in Europe, the UK, and New Zealand, with ongoing efforts for U.S. FDA approval through the FINALE pivotal trial [4] Strategic Partnership - Kebomed, a leading independent distributor of medical devices in Europe, will leverage its established infrastructure and expertise in women's health to drive the adoption of FemBloc [2][6] - The partnership aims to unlock significant growth potential in key European markets, particularly in France, which represents the largest market opportunity for FemBloc [2][6]

Core Insights - Femasys Inc. has launched the FemSperm Insemination Prep Kit, enhancing the sperm preparation process for FemaSeed Intratubal Insemination, aimed at increasing revenue growth through gynecologist activation [1][2][3] - The introduction of this kit is a significant step in Femasys' strategy to penetrate the underserved fertility market, providing a streamlined in-office solution for gynecologists [2][3] Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally, with a patent-protected portfolio of therapeutic and diagnostic products [4] - The company’s fertility portfolio includes FemaSeed, which is positioned as a first-step infertility treatment, and FemVue, a diagnostic tool for fallopian tube assessment [4] Product Details - The FemSperm Insemination Prep Kit allows gynecologists to perform sperm preparation and offer FemaSeed Intratubal Insemination directly in their practices, addressing the needs of an estimated 10 million U.S. women facing infertility [3] - FemaSeed has demonstrated more than double the pregnancy rates of traditional intrauterine insemination (IUI) in cases of low male sperm count, making it a safer and cost-effective alternative to IVF [3][4] Market Strategy - The commercialization of FemBloc, a non-surgical permanent birth control method, has received regulatory approvals in Europe, the UK, and New Zealand, with plans for strategic partnerships to enhance market presence [5] - Femasys aims to broaden patient access to fertility treatments and strengthen its long-term revenue growth strategy by positioning FemaSeed as a first-step treatment before IVF [2][3]